Evidence map›Paper›PMID 27239216›Full record

ReviewEvidence-based complementary and alternative medicine : eCAM2016

Chinese Herbal Medicine as an Adjunctive Therapy for Breast Cancer: A Systematic Review and Meta-Analysis.

Libing Zhu, Lingru Li, Yingshuai Li, Ji Wang, Qi Wang

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Evidence-based complementary and alternative medicine : eCAM, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 7 pooled it
10.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 7 syntheses or guidelines pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. A Network Pharmacology Study on the Molecular Mechanisms of FDY003 for Breast Cancer Treatment.Evidence-based complementary and alternative medicine : eCAM · 2021
    Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Libing ZhuCenter of Reproductive Medicine and Traditional Chinese Medicine Constitution, School of Preclinical Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
Lingru LiCenter of Reproductive Medicine and Traditional Chinese Medicine Constitution, School of Preclinical Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
Yingshuai LiCenter of Reproductive Medicine and Traditional Chinese Medicine Constitution, School of Preclinical Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
Ji WangCenter of Reproductive Medicine and Traditional Chinese Medicine Constitution, School of Preclinical Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
Qi WangCenter of Reproductive Medicine and Traditional Chinese Medicine Constitution, School of Preclinical Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
Beijing University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chinese herbal medicine (CHM) has been widely used as an adjunctive therapy for breast cancer, while its efficacy remains unexplored. The purpose of this study is to evaluate the efficacy of CHM combined with chemotherapy for breast cancer. The study results showed that CHM combined with chemotherapy significantly increased tumor response and KPS as compared to using chemotherapy alone (RR = 1.36; 95% CI = 1.24-1.48; P < 0.00001; RR = 1.38; 95% CI = 1.26-1.52; P < 0.00001, resp.). Besides, CHM as an adjunctive therapy significantly reduced the nausea and vomiting at toxicity grade of III-IV (RR = 0.37; 95% CI = 0.27-0.52; P < 0.00001). Moreover, the combined therapy significantly prevented the decline of WBC in patients under chemotherapy at toxicity grade of III-IV (RR = 0.49; 95% CI = 0.34-0.69; P < 0.00001) and prevented the decline of platelet at toxicity grade of III-IV or I-IV (RR = 0.29; 95% CI = 0.12-0.73; P = 0.008; RR = 0.77; 95% CI = 0.63-0.94; P = 0.009, resp.). This study suggests that CHM combined with chemotherapy in comparison with chemotherapy alone can significantly enhance tumor response, improve KPS, and alleviate toxicity induced by chemotherapy in breast cancer patients. However, a firm conclusion could not be reached due to the lack of high quality trials and large-scale RCTs, so further trials with higher quality and larger scale are needed.

Identifiers

PMID27239216
PMCPMC4876224
OpenAlexW2346927384

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.